

## HR 2455

### Ensuring Timely Access to Generics Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 1, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (May 2, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/2455>

## Sponsor

**Name:** Rep. Joyce, John [R-PA-13]

**Party:** Republican • **State:** PA • **Chamber:** House

## Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Brindisi, Anthony [D-NY-22]	D · NY		May 1, 2019
Rep. Crow, Jason [D-CO-6]	D · CO		May 28, 2019
Rep. Waltz, Michael [R-FL-6]	R · FL		May 28, 2019
Rep. Wright, Ron [R-TX-6]	R · TX		May 28, 2019
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Jun 5, 2019
Rep. Smucker, Lloyd [R-PA-11]	R · PA		Jun 13, 2019

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 2, 2019

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
116 S 3384	Related bill	Mar 3, 2020: Read twice and referred to the Committee on Finance.
116 S 1169	Identical bill	Apr 11, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## Ensuring Timely Access to Generics Act of 2019

This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.

The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.

The FDA may establish a timeline for submitting petitions.

### **Actions Timeline**

---

- **May 2, 2019:** Referred to the Subcommittee on Health.
- **May 1, 2019:** Introduced in House
- **May 1, 2019:** Referred to the House Committee on Energy and Commerce.